Back to Directory
Last Updated: 11/06/2026
Scancell
Oxford
Founded 2003
Off-the-shelf cancer immunotherapies targeting solid tumours
Scancell is a clinical-stage biotech developing active immunotherapies and antibody-based therapeutics for cancer.
Its pipeline spans DNA cancer vaccines, peptide immunotherapies and tumour-specific monoclonal antibodies targeting glycans expressed on cancer cells.
Lead programmes iSCIB1+ and Modi-1 are in Phase 2 trials for melanoma and solid tumours respectively. Two antibody assets have been licensed to Genmab.
The company is AIM-listed and was the first UK biotech to partner with the NHS Cancer Vaccine Launchpad.